|
CPSF4 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.8800200000002E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.17999999999152E-06 |
| Normal-vs-Stage2 |
2.335400E-01 |
| Normal-vs-Stage3 |
2.781600E-03 |
| Normal-vs-Stage4 |
2.058100E-03 |
| Stage1-vs-Stage2 |
2.020200E-01 |
| Stage1-vs-Stage3 |
3.032400E-01 |
| Stage1-vs-Stage4 |
8.202200E-01 |
| Stage2-vs-Stage3 |
5.039600E-01 |
| Stage2-vs-Stage4 |
2.247200E-01 |
| Stage3-vs-Stage4 |
3.801600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.94219999999357E-05 |
| Normal-vs-AfricanAmerican |
3.204100E-02 |
| Normal-vs-Asian |
2.411500E-02 |
| Caucasian-vs-AfricanAmerican |
4.403600E-01 |
| Caucasian-vs-Asian |
4.324800E-01 |
| AfricanAmerican-vs-Asian |
9.921400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.77370000000221E-05 |
| Normal-vs-Female |
6.03240000000005E-05 |
| Male-vs-Female |
5.233200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.79280000015092E-07 |
| Normal-vs-Age(41-60Yrs) |
4.919700E-03 |
| Normal-vs-Age(61-80Yrs) |
1.975240E-03 |
| Normal-vs-Age(81-100Yrs) |
4.032600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.065800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.828400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.781150E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.514400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.010200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.037800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.646340E-02 |
| Classical-VS-Follicular |
1.738650E-01 |
| Classical-VS-Other |
2.931400E-01 |
| Classical-VS-Normal |
4.181600E-04 |
| Tall-VS-Follicular |
7.898600E-01 |
| Tall-VS-Other |
7.736800E-01 |
| Tall-VS-Normal |
8.37830000044448E-07 |
| Follicular-VS-Other |
7.217400E-01 |
| Follicular-VS-Normal |
4.046100E-04 |
| Other-VS-Normal |
1.123810E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.115300E-03 |
| Normal-vs-N1 |
3.79449999998727E-06 |
| N0-vs-N1 |
9.244200E-03 |
|
|
